Amendment 2026-0842s to SB465 (2026)

Classifying xylazine as a schedule III controlled drug.


Revision: Feb. 18, 2026, 3:31 p.m.

Senate Judiciary

February 18, 2026

2026-0842s

09/05

 

 

Amendment to SB 465-FN

 

Amend the bill by replacing section 1 with the following:  

 

1  New Section; Controlled Drug Act; Xylazine.  Amend RSA 318-B by inserting after section 1-c the following new section:  

318-B:1-d  Xylazine.

I.  Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of health and human services, xylazine shall be scheduled as a schedule III controlled drug.

II.  Notwithstanding paragraph I, nothing in this section shall prevent any licensed veterinarian, as defined in RSA 332-B:1, from doing any of the following:  

(a)  Dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b.  

(b)  Dispensing or prescribing for, or administering to, a nonhuman species that is permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b(a)(4).  

(c)  Another use that is approved or permissible under the Federal Food, Drug, and Cosmetic Act.